A review study reported that lactylation modifications regulate both histone and non‐histone proteins, influencing tumor metabolism, immune evasion, and drug resistance.[52] Small molecules like tubuloside A inhibit HCC progression by blocking ABCF1 (ATP binding cassette subfamily F member 1)‐K430la modification,[53] while LDHA or MCT1 (Monocarboxylate transporter 1) inhibition reduced lactylation levels and reversed chemotherapy resistance.[52, 54] These findings establish lactylation as a viable target for precision therapy. The gene discussed is SLC16A1; the disease is hepatocellular carcinoma.